Long-term safety of intravenous human umbilical cord blood-derived mesenchymal stem cell therapy in rheumatoid arthritis: a 5-year follow-up study
Stem Cells Translational Medicine · 2026
DOI: 10.1093/stcltm/szag062 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Stem Cells Translational Medicine, 2026. Verfasst von Eun Hye Park und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Rheumatology, Chung-Ang University College of Medicine, Seoul 06974, Republic of Korea. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells, Fetal Blood. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kangstem Biotech.
Abstract (Originalsprache)
Background/purpose Mesenchymal stem cell (MSC) therapy offers promise for treating autoimmune diseases due to its strong immunomodulatory effects. We investigated the long-term safety of a single intravenous injection with human umbilical cord blood-derived (hUCB)-MSCs in patients with rheumatoid arthritis (RA).
Methods
Patients with RA who met the 2010 ACR/EULAR classification criteria and received a single intravenous infusion of hUCB-MSCs (2.5 × 107, 5.0 × 107, 1.0 × 108 cells) in a phase I trial (NCT02221258) entered this 5-year observational pilot study. Safety assessments were performed at 3, 6, and 12 months after infusion and annually thereafter. Safety endpoints included overall adverse events (AEs), serious adverse events (SAEs), and AEs of special interest.
Results
Nine patients were treated. The most common AEs were osteoarthritis (44.4%) and nasopharyngitis (44.4%). SAEs occurred in 5 patients (55.6%); a serious infection (cellulitis) occurred in 1 patient in the 1.0 × 108 group and resolved after treatment. Benign ovarian and breast tumors were reported in 2 patients 3 years post-infusion. No deaths, thromboembolism, or malignancies occurred during the follow-up period. Laboratory findings remained stable except for 1 case each of transient hypertriglyceridemia and mild eosinophilia. While DAS28 improved markedly by 3-6 months, disease activity gradually increased over 5 years, suggesting waning efficacy after a single infusion.
Conclusion
The long-term safety profile of a single dose of intravenous hUCB-MSC in patients with RA appears acceptable; however, repeated-dose regimens may be needed for sustained disease control and further safety evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Rheumatology, Chung-Ang University College of Medicine, Seoul 06974, Republic of Korea.
- Department of Internal Medicine, Division of Rheumatology, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong 14353, Republic of Korea.
- Department of Internal Medicine, Division of Rheumatology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul 07061, Republic of Korea.
- Institute for Stem Cell Regenerative Medicine, Kangstem Biotech, Seoul 06181, Republic of Korea.
- Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul 08826, Republic of Korea.
- Department of Internal Medicine, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea.
ORCID-Profile: Eun Hye Park, Kichul Shin
Förderung
- Kangstem Biotech
Zitieren
APA
Park, E. H., Kim, M. J., Kang, K. S., & Shin, K. (2026). Long-term safety of intravenous human umbilical cord blood-derived mesenchymal stem cell therapy in rheumatoid arthritis: a 5-year follow-up study. Stem Cells Translational Medicine. https://doi.org/10.1093/stcltm/szag062
Vancouver
Park EH, Kim MJ, Kang KS, Shin K. Long-term safety of intravenous human umbilical cord blood-derived mesenchymal stem cell therapy in rheumatoid arthritis: a 5-year follow-up study. Stem Cells Translational Medicine. 2026. doi:10.1093/stcltm/szag062
BibTeX
@article{Park2026,
author = {Park, Eun Hye and Kim, Min Jung and Kang, Kyung-Sun and Shin, Kichul},
title = {Long-term safety of intravenous human umbilical cord blood-derived mesenchymal stem cell therapy in rheumatoid arthritis: a 5-year follow-up study},
journal = {Stem Cells Translational Medicine},
year = {2026},
doi = {10.1093/stcltm/szag062}
}
EUVIMED